FDA approves immunotherapy that may help some rectal cancer patients avoid surgery

The FDA granted accelerated approval to Jemperli (dostarlimab-gxly), an immunotherapy by GSK, for adults with stage II or III locally advanced rectal cancer characterized by dMMR or MSI-H genetic markers. This treatment may allow eligible patients to avoid chemotherapy, radiation, and surgery, significantly reducing associated quality-of-life impacts.

This Wire brief sits within Fusion42's coverage of Biotech, and 16 sources have reported it between 19 Oct 2026 and 27 Oct 2026.